May 13 |
Tourmaline Bio GAAP EPS of -$0.55
|
May 13 |
Tourmaline Bio Reports First Quarter 2024 Financial Results and Recent Business Highlights
|
Apr 2 |
Avalo Therapeutics Appoints Biotech Leaders to Board of Directors
|
Mar 22 |
Tourmaline Bio: Sinking On Rival's Stodgy Data - I'm Slightly Bearish
|
Mar 19 |
Tourmaline Bio GAAP EPS of -$8.87
|
Mar 19 |
Tourmaline Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
|
Mar 1 |
Bullish Tourmaline Bio Insiders Loaded Up On US$643.3k Of Stock
|
Feb 27 |
Tourmaline Bio to Present at Upcoming Investor Conferences
|
Feb 1 |
Tourmaline Bio to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference
|
Jan 29 |
Tourmaline Bio Announces Closing of $172.5 Million Public Offering of Common Stock, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
|